[go: up one dir, main page]

UA112422C2 - Заміщений натрій-1h-піразол-5-олат - Google Patents

Заміщений натрій-1h-піразол-5-олат

Info

Publication number
UA112422C2
UA112422C2 UAA201307718A UAA201307718A UA112422C2 UA 112422 C2 UA112422 C2 UA 112422C2 UA A201307718 A UAA201307718 A UA A201307718A UA A201307718 A UAA201307718 A UA A201307718A UA 112422 C2 UA112422 C2 UA 112422C2
Authority
UA
Ukraine
Prior art keywords
pyrazol
diseases
olat
substituted sodium
sodium
Prior art date
Application number
UAA201307718A
Other languages
English (en)
Inventor
Ханс-Крістіан Мілітцер
Йорг Грис
Штефан Кьоп
Original Assignee
Баєр Інтеллекчуел Проперті Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA112422(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Баєр Інтеллекчуел Проперті Гмбх filed Critical Баєр Інтеллекчуел Проперті Гмбх
Publication of UA112422C2 publication Critical patent/UA112422C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Даний винахід стосується натрій-1-[6-(морфолін-4-іл)піримідин-4-іл]-4-(1Н-1,2,3-триазол-1-іл)-1Н-піразол-5-олату, способу його одержання, його застосування для лікування та/або профілактики захворювань, а також його застосування для одержання лікарських засобів для лікування та/або профілактики захворювань, зокрема серцево-судинних і гематологічних захворювань, захворювань нирок, а також для сприяння загоєнню ран.
UAA201307718A 2010-11-18 2011-11-15 Заміщений натрій-1h-піразол-5-олат UA112422C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010044131A DE102010044131A1 (de) 2010-11-18 2010-11-18 Substituiertes Natrium-1H-pyrazol-5-olat
PCT/EP2011/070099 WO2012065967A1 (de) 2010-11-18 2011-11-15 Substítuiertes natrium-1h-pyrazol-5-olat

Publications (1)

Publication Number Publication Date
UA112422C2 true UA112422C2 (uk) 2016-09-12

Family

ID=44999768

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201307718A UA112422C2 (uk) 2010-11-18 2011-11-15 Заміщений натрій-1h-піразол-5-олат

Country Status (46)

Country Link
US (2) US8653074B2 (uk)
EP (1) EP2640718B8 (uk)
JP (1) JP5918779B2 (uk)
KR (2) KR20180023043A (uk)
CN (2) CN103270031B (uk)
AP (1) AP3429A (uk)
AR (1) AR083887A1 (uk)
AU (1) AU2011331305B2 (uk)
BR (1) BR112013012223B1 (uk)
CA (1) CA2818002C (uk)
CL (1) CL2013001390A1 (uk)
CO (1) CO6741155A2 (uk)
CR (1) CR20130196A (uk)
CU (1) CU20130072A7 (uk)
CY (1) CY1120375T1 (uk)
DE (1) DE102010044131A1 (uk)
DK (1) DK2640718T3 (uk)
DO (1) DOP2013000096A (uk)
EA (1) EA023103B1 (uk)
EC (1) ECSP13012627A (uk)
ES (1) ES2675580T3 (uk)
GT (1) GT201300125A (uk)
HK (1) HK1210776A1 (uk)
HR (1) HRP20180993T1 (uk)
HU (1) HUE038024T2 (uk)
IL (1) IL226192A (uk)
JO (1) JOP20110347B1 (uk)
LT (1) LT2640718T (uk)
MA (1) MA34671B1 (uk)
MX (1) MX347670B (uk)
MY (1) MY167219A (uk)
NZ (1) NZ610614A (uk)
PE (2) PE20140391A1 (uk)
PH (1) PH12013500997A1 (uk)
PL (1) PL2640718T3 (uk)
PT (1) PT2640718T (uk)
RS (1) RS57599B1 (uk)
SG (1) SG189975A1 (uk)
SI (1) SI2640718T1 (uk)
TN (1) TN2013000215A1 (uk)
TR (1) TR201806652T4 (uk)
TW (1) TWI516485B (uk)
UA (1) UA112422C2 (uk)
UY (1) UY33736A (uk)
WO (1) WO2012065967A1 (uk)
ZA (1) ZA201304430B (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
DK2847183T3 (en) * 2012-05-08 2017-10-02 Bayer Pharma AG PROCEDURE FOR MAKING TRIAZOL COMPOUNDS
MA38974B2 (fr) * 2013-10-17 2020-11-30 Bayer Pharma AG Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate
PL3197442T3 (pl) 2014-09-26 2020-02-28 The Cleveland Clinic Foundation Leczenie i zapobieganie chorobie czynnikami obniżającymi TMA i TMAO
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
WO2018149929A1 (en) * 2017-02-16 2018-08-23 Bayer Pharma Aktiengesellschaft Combination of reporter gene assays and transcriptional analysis
EP3888684A1 (en) * 2020-03-31 2021-10-06 Bayer Animal Health GmbH Composition having improved voluntary acceptance

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1519069A (fr) 1966-04-13 1968-03-29 Geigy Ag J R Dérivés du sulfanilamide et leur préparation
GR63123B (en) 1975-12-11 1979-09-11 Lilly Co Eli Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
US4075003A (en) 1975-12-11 1978-02-21 Eli Lilly And Company Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (pl) 1976-09-20 1979-06-30 Lilly Co Eli Srodek chwastobojczy
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de) 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazol-derivate
DE4204919A1 (de) 1992-02-19 1993-08-26 Bayer Ag Verfahren zur herstellung von 2-chlor-5-alkylaminomethyl-pyridinen
JPH0735361B2 (ja) * 1993-09-09 1995-04-19 日産化学工業株式会社 ヒドラゾン誘導体およびその製造方法
FR2725988B1 (fr) 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH10306077A (ja) 1997-05-07 1998-11-17 Daiichi Rajio Isotope Kenkyusho:Kk ビピラゾール誘導体並びにこれを有効成分とする医薬および試薬
DE19909237A1 (de) 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-on-derivate
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
ES2329453T3 (es) 2001-05-15 2009-11-26 Ortho Mcneil Janssen Pharm Cebado ex-vivo para generar linfocitos t citotoxicos especificos del ligando cd40 para tratar enfermedades autoinmunitarias y alergicas.
AU2002308748A1 (en) 2001-05-16 2002-11-25 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
IL160081A0 (en) 2001-09-21 2004-06-20 Solvay Pharm Bv Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
ES2295441T3 (es) 2001-12-18 2008-04-16 MERCK & CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
UY27813A1 (es) * 2002-05-31 2003-12-31 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2522441A1 (en) 2003-03-27 2004-10-14 Emory University Hif-1 inhibitors
WO2004089303A2 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2004236690A1 (en) 2003-05-01 2004-11-18 Panacea Pharmaceuticals, Inc. Methods of treating ischemic related conditions
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
WO2006088491A2 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
DE102008020113A1 (de) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
EP1861375A1 (en) 2005-03-16 2007-12-05 Aventis Pharmaceuticals Inc. Dipyrazoles as central nervous system agents
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007121687A1 (en) 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
NZ610614A (en) 2015-05-29
EP2640718B1 (de) 2018-03-28
RS57599B1 (sr) 2018-11-30
TN2013000215A1 (en) 2014-11-10
SI2640718T1 (en) 2018-08-31
PL2640718T3 (pl) 2018-08-31
US20130310381A1 (en) 2013-11-21
CN103270031A (zh) 2013-08-28
AP3429A (en) 2015-09-30
CO6741155A2 (es) 2013-08-30
CN104650047A (zh) 2015-05-27
MY167219A (en) 2018-08-14
AR083887A1 (es) 2013-03-27
ECSP13012627A (es) 2013-07-31
ZA201304430B (en) 2014-12-23
JP5918779B2 (ja) 2016-05-18
HK1210776A1 (en) 2016-05-06
CN103270031B (zh) 2015-06-17
AP2013006922A0 (en) 2013-06-30
IL226192A (en) 2016-06-30
BR112013012223B1 (pt) 2021-06-29
GT201300125A (es) 2017-07-26
HK1188782A1 (en) 2014-05-16
CY1120375T1 (el) 2019-07-10
KR20130131335A (ko) 2013-12-03
KR101984317B1 (ko) 2019-05-30
TR201806652T4 (tr) 2018-06-21
ES2675580T3 (es) 2018-07-11
KR20180023043A (ko) 2018-03-06
CR20130196A (es) 2013-08-06
MX347670B (es) 2017-05-03
TW201307328A (zh) 2013-02-16
LT2640718T (lt) 2018-07-10
DK2640718T3 (da) 2018-07-16
TWI516485B (zh) 2016-01-11
EP2640718A1 (de) 2013-09-25
DE102010044131A1 (de) 2012-05-24
CU20130072A7 (es) 2013-09-27
CA2818002A1 (en) 2012-05-24
PH12013500997A1 (en) 2015-03-06
DOP2013000096A (es) 2013-06-15
US9533972B2 (en) 2017-01-03
HUE038024T2 (hu) 2018-09-28
AU2011331305B2 (en) 2016-06-02
WO2012065967A1 (de) 2012-05-24
CL2013001390A1 (es) 2014-04-04
PE20180324A1 (es) 2018-02-13
SG189975A1 (en) 2013-06-28
EP2640718B8 (de) 2018-06-27
CA2818002C (en) 2019-01-15
UY33736A (es) 2012-06-29
EA023103B1 (ru) 2016-04-29
AU2011331305A1 (en) 2013-06-06
US8653074B2 (en) 2014-02-18
HRP20180993T1 (hr) 2018-08-10
MA34671B1 (fr) 2013-11-02
JOP20110347B1 (ar) 2021-08-17
MX2013004797A (es) 2013-06-28
PE20140391A1 (es) 2014-03-29
IL226192A0 (en) 2013-07-31
US20120129857A1 (en) 2012-05-24
PT2640718T (pt) 2018-07-04
EA201390703A1 (ru) 2013-12-30
BR112013012223A2 (pt) 2020-03-10
JP2014500877A (ja) 2014-01-16

Similar Documents

Publication Publication Date Title
UA112422C2 (uk) Заміщений натрій-1h-піразол-5-олат
EA201290836A1 (ru) Связанные бис-арильные арилтриазолоны и их применение
UA105487C2 (uk) Заміщені дигідропіразолони як інгібітори hif-проліл-4-гідроксилази
MY169564A (en) Substituted dihydropyrazolones and their use
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
UA105290C2 (uk) АПТАМЕРИ ДО β-NGF І ЇХ ЗАСТОСУВАННЯ ПРИ ЛІКУВАННІ β-NGF-ОПОСЕРЕДКОВАНИХ ЗАХВОРЮВАНЬ І РОЗЛАДІВ
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
EA201790951A1 (ru) Производные гидроксиалкилзамещенного фенилтриазола и их применение
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EA020330B3 (ru) Хиназолиновые соединения
AU2011328009A8 (en) Compounds and methods for treating pain
EA201600288A1 (ru) Замещенные фенилаланиновые производные
EA201190312A1 (ru) Замещенные пиперидины
EA201190313A1 (ru) Замещенные пиперидины
EA201390925A1 (ru) Производные санглиферина и способы их получения
EA201200028A1 (ru) Альфа-1 мультимеры hla-g и их фармацевтическое применение
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
UA107920C2 (uk) Заміщені піримідини, призначені для лікування захворювань, таких як рак